细胞因子是关键所在：细胞因子释放综合征是CAR-T细胞心血管效应的基础。 - Suppr

Suppr

超能文献

Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell.

作者信息

Catino Anna B

机构信息

Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah, USA.

出版信息

JACC CardioOncol. 2020 Jun 16;2(2):204-206. doi: 10.1016/j.jaccao.2020.05.006. eCollection 2020 Jun.

DOI:10.1016/j.jaccao.2020.05.006

PMID:34396229

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352284/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137c/8352284/ec02924956f8/fx1.jpg

相似文献

Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell.细胞因子是关键所在：细胞因子释放综合征是CAR-T细胞心血管效应的基础。

JACC CardioOncol. 2020 Jun 16;2(2):204-206. doi: 10.1016/j.jaccao.2020.05.006. eCollection 2020 Jun.

T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.T 细胞免疫疗法与心血管疾病：嵌合抗原受体 T 细胞和双特异性 T 细胞衔接器疗法。

Heart Fail Clin. 2022 Jul;18(3):443-454. doi: 10.1016/j.hfc.2022.02.008.

Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias.嵌合抗原受体T细胞疗法的心血管并发症：细胞因子释放综合征及相关心律失常

J Immunother Precis Oncol. 2020 Jul 20;3(3):113-120. doi: 10.36401/JIPO-20-10. eCollection 2020 Aug.

Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.嵌合抗原受体 T 细胞（CAR-T）疗法的心脏毒性：病理生理学、临床意义和超声心动图评估。

Int J Mol Sci. 2022 Jul 26;23(15):8242. doi: 10.3390/ijms23158242.

[Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report].[急性淋巴细胞白血病患者嵌合抗原受体T细胞疗法相关细胞因子释放综合征的体外细胞因子清除。病例报告]

Ter Arkh. 2021 Jul 23;93(7):811-817. doi: 10.26442/00403660.2021.07.200931.

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.嵌合抗原受体T细胞疗法治疗晚期恶性肿瘤的心脏毒性。

Eur Heart J. 2022 May 21;43(20):1928-1940. doi: 10.1093/eurheartj/ehac106.

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management.与抗CD19嵌合抗原受体T细胞（CAR-T）疗法相关的心脏毒性：识别、危险因素及管理

Diseases. 2021 Mar 17;9(1):20. doi: 10.3390/diseases9010020.

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病后的细胞因子释放综合征

Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.

The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.嵌合抗原受体 T 细胞疗法的心血管并发症。

Curr Hematol Malig Rep. 2020 Apr;15(2):130-132. doi: 10.1007/s11899-020-00567-4.

Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.嵌合抗原受体 T 细胞治疗接受者的生物标志物和心血管结局。

Eur Heart J. 2023 Jun 9;44(22):2029-2042. doi: 10.1093/eurheartj/ehad117.

引用本文的文献

Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy.革新心脏纤维化治疗：个性化嵌合抗原受体T细胞疗法的潜力

Cardiooncology. 2025 Aug 22;11(1):76. doi: 10.1186/s40959-025-00367-w.

Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study.接受CAR-T细胞疗法治疗的患者中主要不良心血管事件的发生率：一项前瞻性研究。

JACC CardioOncol. 2023 Oct 10;5(6):747-754. doi: 10.1016/j.jaccao.2023.07.009. eCollection 2023 Dec.

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.2022 年中国抗 CD19 嵌合抗原受体 T 细胞治疗 B 细胞非霍奇金淋巴瘤毒性管理临床专家共识及指南

Cancer Biol Med. 2023 Mar 2;20(2):129-46. doi: 10.20892/j.issn.2095-3941.2022.0585.

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy.嵌合抗原受体T细胞（CAR-T）疗法继发的细胞因子释放综合征和神经毒性中的白细胞介素抑制剂

Diseases. 2022 Jul 6;10(3):41. doi: 10.3390/diseases10030041.

Transient left ventricular dysfunction following chimeric antigen receptor T-cell-mediated encephalopathy: A form of stress cardiomyopathy.嵌合抗原受体T细胞介导的脑病后短暂性左心室功能障碍：应激性心肌病的一种形式。

EJHaem. 2021 Dec 14;3(1):231-234. doi: 10.1002/jha2.369. eCollection 2022 Feb.

Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome.细胞因子释放综合征中多器官功能障碍的潜在病理生理学机制。

Mediators Inflamm. 2022 Apr 6;2022:7137900. doi: 10.1155/2022/7137900. eCollection 2022.

本文引用的文献

CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?嵌合抗原受体T细胞疗法相关的心血管结局与管理：全身性疾病还是直接心脏毒性？

JACC CardioOncol. 2020 Mar 17;2(1):97-109. doi: 10.1016/j.jaccao.2020.02.011. eCollection 2020 Mar.

Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study.嵌合抗原受体T细胞疗法的心血管效应：一项回顾性研究

JACC CardioOncol. 2020 Jun;2(2):193-203. doi: 10.1016/j.jaccao.2020.04.012. Epub 2020 Jun 16.

Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.嵌合抗原受体 T 细胞疗法治疗癌症和心脏：JACC 理事会观点。

J Am Coll Cardiol. 2019 Dec 24;74(25):3153-3163. doi: 10.1016/j.jacc.2019.10.049.

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).嵌合抗原受体 T 细胞（CAR-T）治疗的成年人中的心血管事件。

J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108. doi: 10.1016/j.jacc.2019.10.038.

CAR T cell therapy: inroads to response and resistance.嵌合抗原受体T细胞疗法：通向应答与耐药之路

Nat Rev Immunol. 2019 Feb;19(2):73-74. doi: 10.1038/s41577-018-0119-y.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.

Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience.嵌合抗原受体 T 细胞疗法在儿童中的心脏表现：单中心经验。

Biol Blood Marrow Transplant. 2018 Aug;24(8):1590-1595. doi: 10.1016/j.bbmt.2018.05.014. Epub 2018 May 14.

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。

Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.

Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.用于血液系统恶性肿瘤的靶向CD19嵌合抗原受体T细胞疗法：解读迄今为止的临床结果

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验